<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031729</url>
  </required_header>
  <id_info>
    <org_study_id>2019P001809</org_study_id>
    <nct_id>NCT04031729</nct_id>
  </id_info>
  <brief_title>Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Aspirin in Adults With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the
      absence of excess alcohol consumption, affects an estimated 30% of adults in the United
      States. A proportion of people with NAFLD will develop progressive, inflammatory nonalcoholic
      steatohepatitis (NASH), which can progress to liver cirrhosis and liver failure. NAFLD is
      expected to be the most common indication for liver transplantation by the year 2020. We
      hypothesize that among adults with NAFLD, aspirin will reduce intrahepatic lipid content, as
      quantified by 1H magnetic resonance spectroscopy (1H-MRS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent intrahepatic lipid content, quantified by 1H-MRS</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of circulating bioactive lipid mediators</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose (81mg) aspirin tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 to 69 years

          -  NAFLD, defined by confirmed hepatic steatosis by imaging or by liver biopsy, in the
             absence of other causes of hepatic steatosis or significant alcohol consumption. If
             liver imaging or biopsy has not been performed clinically, liver ultrasound assessment
             will be performed as part of the screening visit.

          -  Early-stage liver fibrosis, defined as fibrosis less than or equal to Fibrosis Stage 2
             (F2), confirmed by either (1) a recent liver biopsy or (2) a recent elastography /
             Fibroscan study. If no recent biopsy or elastography/Fibroscan have been performed, a
             Fibroscan will be performed as part of the screening visit.

        Exclusion Criteria:

          -  Liver fibrosis stage &gt; 2

          -  Current aspirin use

          -  Contraindications to aspirin use

          -  Contraindications to magnetic resonance imaging (MRI)

          -  Pregnancy or desire to become pregnant

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracey G Simon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracey G Simon, MD, MPH</last_name>
    <phone>617-724-2401</phone>
    <email>tgsimon@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey G Simon, MD, MPH</last_name>
      <phone>617-724-3416</phone>
      <email>tgsimon@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rasheeda Mohammed</last_name>
      <phone>6177243416</phone>
      <email>rmohammed3@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tracey G. Simon, MD</investigator_full_name>
    <investigator_title>Instructor in Medicine and Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Anti-inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

